74 results
8-K
EX-99.2
GLUE
Monte Rosa Therapeutics Inc
9 May 24
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
7:05am
MILLION Compounds screened Lab experimentation Scalable Data Lake with purpose-built data services for seamless data movement and unified governance Cloud
S-8
GLUE
Monte Rosa Therapeutics Inc
14 Mar 24
Registration of securities for employees
4:08pm
, 2023 (File No. 333-270607).
Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities … on June 25, 2021 (File No. 333-257406) March 29, 2022 (File No. 333-263953) and March 16, 2023 (File No. 333-270607).
Estimated solely for the purpose
8-K
EX-99.2
19yt odxn9
14 Mar 24
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:05am
8-K
EX-4.1
06sw3
26 Oct 23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
5:01pm
8-K
EX-10.1
bupu qlp0gky7tz1yqv0
26 Oct 23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
5:01pm
424B5
9x17 wm6jgo8l0k
26 Oct 23
Prospectus supplement for primary offering
4:55pm
8-K
EX-99.4
t3r ccg730fn12vmn
17 Oct 23
Monte Rosa to receive an upfront payment of $50 million and potential future payments exceeding $2 billion
7:55am
PRE 14A
401rr9
12 Apr 23
Preliminary proxy
4:07pm
S-3
EX-1.2
87dzn7b9kutito r3
1 Jul 22
Shelf registration
5:01pm
S-3
h86ghhexxpvt0g9tj
1 Jul 22
Shelf registration
5:01pm